Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Mehdi H. Hamadani MD

Mehdi H. Hamadani MD profile photo picture

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


Publications (274)

  • Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. (Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M) Hematol Oncol Stem Cell Ther 2020 Oct 08 PMID: 33058787 PMCID: PMC7543702 SCOPUS ID: 2-s2.0-85092735525 10/16/2020    
  • Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P) Nat Med 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020    
  • Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. (Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, Nagler A) Biol Blood Marrow Transplant 2020 Sep 20 PMID: 32966881 09/24/2020    
  • Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. (Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M) Biol Blood Marrow Transplant 2020 Sep 19 PMID: 32956819 SCOPUS ID: 2-s2.0-85093981145 09/22/2020    
  • Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. (Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M) Biol Blood Marrow Transplant 2020 Sep 17 PMID: 32949754 09/20/2020    
  • Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. (Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2020 Sep 11 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020    
  • CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. (Thapa B, Caimi PF, Ardeshna KM, Solh M, Carlo-Stella C, Kahl BS, Hamadani M) Blood Adv 2020 Aug 25;4(16):3850-3852 PMID: 32797191 PMCID: PMC7448593 SCOPUS ID: 2-s2.0-85096132028 08/17/2020    
  • Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. (Badar T, Johnson BD, Hamadani M) Bone Marrow Transplant 2020 Aug 11 PMID: 32782349 SCOPUS ID: 2-s2.0-85089247553 08/13/2020    
  • Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. (Dhakal B, Hari PN, Usmani SZ, Hamadani M) Bone Marrow Transplant 2020 Aug 07 PMID: 32770147 SCOPUS ID: 2-s2.0-85089253834 08/10/2020       1 Citation
  • Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. (Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Nov;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020    
  • Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. (Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee) Biol Blood Marrow Transplant 2020 Dec;26(12):2181-2189 PMID: 32717432 PMCID: PMC7380217 SCOPUS ID: 2-s2.0-85089451061 07/28/2020    
  • Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. (Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W) Blood Adv 2020 Jul 14;4(13):3180-3190 PMID: 32663298 PMCID: PMC7362362 SCOPUS ID: 2-s2.0-85088320644 07/15/2020    
  • Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020    
  • Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. (Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S) Biol Blood Marrow Transplant 2020 Sep;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020       1 Citation
  • Trends in the use of therapeutic plasma exchange in multiple myeloma. (Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P) J Clin Apher 2020 Aug;35(4):307-315 PMID: 32516865 SCOPUS ID: 2-s2.0-85086092696 06/10/2020    
  • Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. (Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M) JAMA Oncol 2020 Jul 01;6(7):1011-1018 PMID: 32496525 PMCID: PMC7273311 SCOPUS ID: 2-s2.0-85086233103 06/05/2020       4 Citations
  • Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. (D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM) Biol Blood Marrow Transplant 2020 Aug;26(8):e177-e182 PMID: 32438042 PMCID: PMC7404814 SCOPUS ID: 2-s2.0-85085969206 05/22/2020       11 Citations
  • Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. (Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M) Br J Haematol 2020 Jul;190(2):e98-e101 PMID: 32415780 SCOPUS ID: 2-s2.0-85084830591 05/18/2020    
  • Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. (Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM) Biol Blood Marrow Transplant 2020 07;26(7):e161-e166 PMID: 32389803 PMCID: PMC7206419 SCOPUS ID: 2-s2.0-85084668943 05/12/2020       3 Citations
  • Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. (Kanate AS, Perales MA, Hamadani M) J Natl Compr Canc Netw 2020 05;18(5):635-643 PMID: 32380457 05/08/2020    
  • Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. (Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M) Br J Haematol 2020 Apr 21 PMID: 32314807 PMCID: PMC7575614 SCOPUS ID: 2-s2.0-85083643436 04/22/2020    
  • Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. (Abedin SM, Hamadani M) Expert Opin Investig Drugs 2020 May;29(5):423-427 PMID: 32293938 SCOPUS ID: 2-s2.0-85083651597 04/16/2020       2 Citations
  • Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. (Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM) Biol Blood Marrow Transplant 2020 07;26(7):1312-1317 PMID: 32283185 PMCID: PMC7194895 SCOPUS ID: 2-s2.0-85083795044 04/14/2020       5 Citations
  • Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. (Rashidi A, Meybodi MA, Cao W, Chu H, Warlick ED, Devine S, Pasquini MC, Weisdorf DJ, Hamadani M) Biol Blood Marrow Transplant 2020 Jun;26(6):e138-e141 PMID: 32171885 SCOPUS ID: 2-s2.0-85083504564 03/17/2020       1 Citation
  • Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. (Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT) Biol Blood Marrow Transplant 2020 Jun;26(6):1099-1105 PMID: 32165327 PMCID: PMC7255948 SCOPUS ID: 2-s2.0-85083523089 03/14/2020       1 Citation
  • Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. (Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, Hamadani M) Biol Blood Marrow Transplant 2020 Jul;26(7):1247-1256 PMID: 32165328 SCOPUS ID: 2-s2.0-85084227379 03/14/2020       6 Citations
  • Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. (Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN) Cancer 2020 Jun 15;126(12):2791-2801 PMID: 32154922 SCOPUS ID: 2-s2.0-85081273628 03/11/2020    
  • Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. (Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 Jul;26(7):1288-1297 PMID: 32135202 SCOPUS ID: 2-s2.0-85083636589 03/07/2020       2 Citations
  • Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. (Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M) Cancer 2020 May 15;126(10):2279-2287 PMID: 32049359 PMCID: PMC7190439 SCOPUS ID: 2-s2.0-85079369077 02/13/2020    
  • Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. (Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang MJ, Gluckman E, Montoto S, Eapen M) J Clin Oncol 2020 May 10;38(14):1518-1526 PMID: 32031876 PMCID: PMC7213591 SCOPUS ID: 2-s2.0-85084380128 02/08/2020       3 Citations
  • Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. (Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW) Blood Adv 2020 02 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020       4 Citations
  • Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020       3 Citations
  • Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation? (Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M, European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)) Biol Blood Marrow Transplant 2020 04;26(4):e77-e85 PMID: 31917272 PMCID: PMC7207150 SCOPUS ID: 2-s2.0-85079050617 01/10/2020       7 Citations
  • Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. (Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS) Blood Adv 2020 01 14;4(1):47-54 PMID: 31899797 PMCID: PMC6960457 SCOPUS ID: 2-s2.0-85078133666 01/04/2020       3 Citations
  • Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. (Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME) J Clin Oncol 2020 Apr 20;38(12):1273-1283 PMID: 31860405 PMCID: PMC7164487 SCOPUS ID: 2-s2.0-85083545151 12/21/2019       24 Citations
  • Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M) Blood Cancer J 2019 12 03;9(12):97 PMID: 31796726 PMCID: PMC6890709 SCOPUS ID: 2-s2.0-85075936084 12/05/2019       1 Citation
  • Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. (Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M) Leuk Lymphoma 2020 04;61(4):869-874 PMID: 31762357 SCOPUS ID: 2-s2.0-85075533403 11/26/2019       2 Citations
  • Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. (Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML) Blood 2020 01 09;135(2):97-107 PMID: 31738834 PMCID: PMC6952830 SCOPUS ID: 2-s2.0-85077761109 11/19/2019       7 Citations
  • A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. (Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA) Clin Cancer Res 2019 12 01;25(23):6986-6994 PMID: 31685491 11/07/2019       12 Citations
  • Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. (DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W) Biol Blood Marrow Transplant 2020 Mar;26(3):472-479 PMID: 31669399 PMCID: PMC7358778 SCOPUS ID: 2-s2.0-85076548681 11/02/2019       1 Citation
  • Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. (Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M) Blood Adv 2019 10 08;3(19):2836-2844 PMID: 31582392 PMCID: PMC6784523 SCOPUS ID: 2-s2.0-85073446898 10/05/2019       11 Citations
  • An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. (Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A) J Clin Apher 2019 Dec;34(6):686-691 PMID: 31566813 PMCID: PMC6957224 SCOPUS ID: 2-s2.0-85073930913 10/01/2019       1 Citation
  • HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. (Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, Hamadani M, Weisdorf DJ, Chu H, Rashidi A) Blood Adv 2019 09 10;3(17):2581-2585 PMID: 31484635 PMCID: PMC6737418 SCOPUS ID: 2-s2.0-85072206849 09/06/2019       5 Citations
  • Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. (Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN) Oncologist 2019 11;24(11):1488-1495 PMID: 31467178 PMCID: PMC6853108 SCOPUS ID: 2-s2.0-85071466837 08/31/2019    
  • Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. (Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Ali Hamidieh A, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D) Hematol Oncol Stem Cell Ther 2020 Mar;13(1):7-16 PMID: 31449781 SCOPUS ID: 2-s2.0-85080069497 08/27/2019       1 Citation
  • Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y) Biol Blood Marrow Transplant 2019 12;25(12):2305-2321 PMID: 31446199 08/26/2019       18 Citations
  • Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. (Epperla N, Hamadani M, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar A) Cancer 2019 Dec 15;125(24):4417-4425 PMID: 31441943 08/24/2019       3 Citations
  • Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. (Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P) Blood Cancer J 2019 07 29;9(8):56 PMID: 31358733 PMCID: PMC6663939 SCOPUS ID: 2-s2.0-85069933026 07/31/2019       2 Citations
  • Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. (Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A) Amyloid 2019 Dec;26(4):210-215 PMID: 31347424 SCOPUS ID: 2-s2.0-85074118154 07/28/2019    
  • A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant. (Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P) Biol Blood Marrow Transplant 2019 10;25(10):e305-e309 PMID: 31295572 07/12/2019    
  • Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. (Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M) JAMA Netw Open 2019 07 03;2(7):e196476 PMID: 31276175 SCOPUS ID: 2-s2.0-85068511187 07/06/2019       2 Citations
  • Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. (Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR) Clin Cancer Res 2019 08 15;25(16):5143-5155 PMID: 31253630 PMCID: PMC6697588 SCOPUS ID: 2-s2.0-85070674030 06/30/2019       1 Citation
  • Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. (Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W) Blood Adv 2019 06 25;3(12):1826-1836 PMID: 31201170 PMCID: PMC6595262 SCOPUS ID: 2-s2.0-85068734856 06/16/2019       26 Citations
  • Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. (Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS) Blood Adv 2019 06 11;3(11):1661-1669 PMID: 31167818 PMCID: PMC6560348 SCOPUS ID: 2-s2.0-85067501987 06/07/2019       6 Citations
  • Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. (Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M) Biol Blood Marrow Transplant 2019 09;25(9):1859-1868 PMID: 31132455 PMCID: PMC6755039 SCOPUS ID: 2-s2.0-85067280149 05/28/2019       22 Citations
  • FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? (Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ, Blood and Marrow Transplant Clinical Trials Network) J Clin Oncol 2019 07 01;37(19):1604-1607 PMID: 31034300 PMCID: PMC6804888 04/30/2019       8 Citations
  • Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. (Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D) Biol Blood Marrow Transplant 2019 12;25(12):2330-2337 PMID: 31002990 SCOPUS ID: 2-s2.0-85065760511 04/20/2019       6 Citations
  • Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 08;25(8):1689-1694 PMID: 30965140 SCOPUS ID: 2-s2.0-85065022222 04/10/2019       20 Citations
  • A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. (D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A) Biol Blood Marrow Transplant 2019 08;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019       5 Citations
  • Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. (Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM) Blood Adv 2019 03 26;3(6):875-883 PMID: 30890544 PMCID: PMC6436017 SCOPUS ID: 2-s2.0-85072746485 03/21/2019       4 Citations
  • Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. (Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S) Biol Blood Marrow Transplant 2019 07;25(7):1456-1464 PMID: 30878605 SCOPUS ID: 2-s2.0-85064323899 03/18/2019       6 Citations
  • Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. (Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, Hamadani M) JAMA Oncol 2019 May 01;5(5):715-722 PMID: 30816957 PMCID: PMC6988125 03/01/2019       14 Citations
  • PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. (Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, Boumendil A, Gopal A, Herrera AF, Schmid C, Diez-Martin JL, Fuchs E, Bolaños-Meade J, Gooptu M, Al Malki MM, Castagna L, Ciurea SO, Dominietto A, Blaise D, Ciceri F, Tischer J, Corradini P, Montoto S, Robinson S, Gülbas Z, Hamadani M) Blood Adv 2019 02 12;3(3):360-369 PMID: 30723110 PMCID: PMC6373757 SCOPUS ID: 2-s2.0-85061139017 02/07/2019       29 Citations
  • Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG) Leukemia 2019 07;33(7):1736-1746 PMID: 30696949 PMCID: PMC6755968 SCOPUS ID: 2-s2.0-85060937214 01/31/2019       16 Citations
  • Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. (Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M) J Hematol Oncol 2019 01 10;12(1):6 PMID: 30630534 PMCID: PMC6329157 SCOPUS ID: 2-s2.0-85059829766 01/12/2019       10 Citations
  • Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. (Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N) Clin Lymphoma Myeloma Leuk 2019 02;19(2):95-102 PMID: 30581160 SCOPUS ID: 2-s2.0-85058679508 12/26/2018       2 Citations
  • Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 04;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.0-85059680507 12/21/2018       9 Citations
  • Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. (Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA) Bone Marrow Transplant 2019 07;54(7):1094-1106 PMID: 30446739 11/18/2018       6 Citations
  • Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. (Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ) Leuk Lymphoma 2019 04;60(4):940-946 PMID: 30277110 SCOPUS ID: 2-s2.0-85054414534 10/03/2018       1 Citation
  • Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. (Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN) Biol Blood Marrow Transplant 2019 01;25(1):e33-e38 PMID: 30244105 SCOPUS ID: 2-s2.0-85055445894 09/24/2018    
  • Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. (Hashmi H, Hamadani M, Awan FT) Expert Opin Pharmacother 2018 10;19(15):1631-1634 PMID: 30200789 09/12/2018       1 Citation
  • Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. (Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK) Leuk Res 2018 11;74:130-136 PMID: 30055822 PMCID: PMC6219911 SCOPUS ID: 2-s2.0-85050340275 07/30/2018       9 Citations
  • Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 08;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018       8 Citations
  • Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. (Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB) Leuk Lymphoma 2018 12;59(12):2862-2870 PMID: 29912594 PMCID: PMC6360945 06/19/2018       3 Citations
  • Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular iymphoma. (Sureda A, Montoto S, Dreger P, Hamadani M, Pasquini MC) Cancer 2018 08;124(16):3455-3456 PMID: 29878309 SCOPUS ID: 2-s2.0-85052190185 06/08/2018    
  • Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. (Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD) BMC Cancer 2018 May 24;18(1):593 PMID: 29793446 PMCID: PMC5968588 SCOPUS ID: 2-s2.0-85047544800 05/26/2018       10 Citations
  • Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. (Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P) Biol Blood Marrow Transplant 2018 08;24(8):1610-1614 PMID: 29751116 SCOPUS ID: 2-s2.0-85048069667 05/12/2018       4 Citations
  • Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. (D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P) Contemp Clin Trials Commun 2017 Dec;8:33-38 PMID: 29696194 PMCID: PMC5898504 SCOPUS ID: 2-s2.0-85027981960 04/27/2018    
  • Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. (Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M) Blood Adv 2018 04 24;2(8):933-940 PMID: 29685953 PMCID: PMC5916010 SCOPUS ID: 2-s2.0-85055419410 04/25/2018       16 Citations
  • Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. (Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2018 08;24(8):1664-1670 PMID: 29680516 SCOPUS ID: 2-s2.0-85047194888 04/24/2018       17 Citations
  • Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. (Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A) Bone Marrow Transplant 2018 09;53(9):1210-1213 PMID: 29679076 SCOPUS ID: 2-s2.0-85045751124 04/22/2018       3 Citations
  • Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. (Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M) Cancer 2018 06 15;124(12):2541-2551 PMID: 29645093 PMCID: PMC5990449 SCOPUS ID: 2-s2.0-85045242474 04/13/2018       19 Citations
  • ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. (Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA) Biol Blood Marrow Transplant 2018 06;24(6):1119-1124 PMID: 29608957 SCOPUS ID: 2-s2.0-85046667868 04/03/2018       9 Citations
  • Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. (Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB) Cancer 2018 06 01;124(11):2306-2315 PMID: 29579328 PMCID: PMC5992038 03/27/2018       6 Citations
  • Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. (Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ) Lancet Haematol 2018 Apr;5(4):e170-e180 PMID: 29550382 PMCID: PMC7029813 03/20/2018       19 Citations
  • What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. (Shah NN, Fenske TS, Hamadani M, Svoboda J) Br J Haematol 2019 03;184(5):838-840 PMID: 29528099 SCOPUS ID: 2-s2.0-85043472454 03/13/2018    
  • Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. (McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, Hamadani M, Norkin M, Perales MA, Reshef R, Rocha V, Romee R, Solh M, Urbano-Ispizua A, Waller EK, Fuchs EJ, Eapen M) Blood Adv 2018 02 13;2(3):299-307 PMID: 29440002 PMCID: PMC5812334 SCOPUS ID: 2-s2.0-85050645336 02/15/2018       39 Citations
  • Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. (Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, Hamadani M, Pasquini MC) Cancer 2018 04 15;124(8):1733-1742 PMID: 29424927 PMCID: PMC5946312 SCOPUS ID: 2-s2.0-85041530897 02/10/2018       21 Citations
  • Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. (Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V) Biol Blood Marrow Transplant 2018 05;24(5):983-988 PMID: 29410340 SCOPUS ID: 2-s2.0-85042234569 02/08/2018       4 Citations
  • Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. (Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, Hamadani M, Tamari R, Anderton K, Dixon P, Giralt SA) Biol Blood Marrow Transplant 2018 07;24(7):1379-1385 PMID: 29410301 PMCID: PMC7590532 SCOPUS ID: 2-s2.0-85046706138 02/08/2018       4 Citations
  • Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. (Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M) Haematologica 2018 04;103(4):717-727 PMID: 29351985 PMCID: PMC5865423 SCOPUS ID: 2-s2.0-85044420638 01/21/2018       15 Citations
  • Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. (Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE) Bone Marrow Transplant 2018 05;53(5):535-555 PMID: 29343837 PMCID: PMC5985976 SCOPUS ID: 2-s2.0-85040684681 01/19/2018       19 Citations
  • Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. (Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN) JAMA Oncol 2018 Mar 01;4(3):343-350 PMID: 29302684 PMCID: PMC5885822 SCOPUS ID: 2-s2.0-85045789349 01/06/2018       52 Citations
  • R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. (Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J) Br J Haematol 2018 02;180(4):534-544 PMID: 29265182 SCOPUS ID: 2-s2.0-85038422379 12/22/2017       26 Citations
  • The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. (Rezahosseini O, Hanaei S, Hamadani M, Keshavarz-Fathi M, Rezaei N) Int Rev Immunol 2018 05 04;37(3):165-173 PMID: 29257907 12/20/2017       1 Citation
  • Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. (Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M) Biol Blood Marrow Transplant 2018 06;24(6):1163-1171 PMID: 29242111 PMCID: PMC5993598 SCOPUS ID: 2-s2.0-85040541734 12/16/2017       46 Citations
  • Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All? (Hamadani M, Horowitz MM) J Oncol Pract 2017 12;13(12):798-806 PMID: 29232542 PMCID: PMC5728364 12/13/2017       4 Citations
  • Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. (Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, Ganguly S) Biol Blood Marrow Transplant 2018 03;24(3):486-493 PMID: 29225164 12/12/2017       1 Citation
  • Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. (Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P) Cancer 2018 02 15;124(4):816-825 PMID: 29125192 PMCID: PMC5871233 SCOPUS ID: 2-s2.0-85033592450 11/11/2017       22 Citations
  • Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). (Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P) J Hematol Oncol 2017 11 02;10(1):171 PMID: 29096668 PMCID: PMC5668956 11/04/2017       17 Citations
  • Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. (Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P) Biol Blood Marrow Transplant 2018 03;24(3):478-485 PMID: 29079457 PMCID: PMC5826888 SCOPUS ID: 2-s2.0-85035213070 10/29/2017       18 Citations
  • Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. (Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2018 01;24(1):78-85 PMID: 29032272 PMCID: PMC5743624 SCOPUS ID: 2-s2.0-85034849252 10/17/2017       3 Citations
  • Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. (Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S) Br J Haematol 2017 12;179(5):781-789 PMID: 28980314 SCOPUS ID: 2-s2.0-85035114874 10/06/2017       27 Citations
  • Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. (Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE) Biol Blood Marrow Transplant 2018 02;24(2):228-241 PMID: 28939455 PMCID: PMC5768142 SCOPUS ID: 2-s2.0-85034852162 09/25/2017       13 Citations
  • Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. (Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB) Transfusion 2017 11;57(11):2775-2781 PMID: 28836275 08/25/2017       6 Citations
  • Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. (Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A) Hematol Oncol Stem Cell Ther 2018 Jun;11(2):105-111 PMID: 28830801 SCOPUS ID: 2-s2.0-85027963716 08/24/2017       3 Citations
  • Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN) Biol Blood Marrow Transplant 2017 Nov;23(11):1826-1838 PMID: 28797780 08/12/2017       61 Citations
  • Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. (Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M) Br J Haematol 2018 09;182(6):916-920 PMID: 28771676 PMCID: PMC5796874 08/05/2017       23 Citations
  • Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. (Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR) Biol Blood Marrow Transplant 2017 Nov;23(11):1955-1960 PMID: 28757436 SCOPUS ID: 2-s2.0-85028446880 08/02/2017       7 Citations
  • Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. (Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2017 07;17(7):408-414 PMID: 28756899 SCOPUS ID: 2-s2.0-85026407137 08/02/2017       6 Citations
  • Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. (Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P) Haematologica 2017 10;102(10):1767-1775 PMID: 28751562 PMCID: PMC5622861 07/29/2017       28 Citations
  • C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. (Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ) Cancer 2017 11 15;123(22):4411-4418 PMID: 28749548 SCOPUS ID: 2-s2.0-85026327949 07/28/2017       13 Citations
  • Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 SCOPUS ID: 2-s2.0-85026445343 07/13/2017       3 Citations
  • Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. (D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P) Leukemia 2017 09;31(9):1998-2000 PMID: 28663578 PMCID: PMC5587375 SCOPUS ID: 2-s2.0-85028872119 07/01/2017       12 Citations
  • Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. (Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M) J Clin Oncol 2017 Sep 10;35(26):3002-3009 PMID: 28644773 PMCID: PMC5590802 SCOPUS ID: 2-s2.0-85029169856 06/24/2017       115 Citations
  • Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. (Epperla N, Hamadani M) Hematol Oncol Stem Cell Ther 2017 Dec;10(4):277-284 PMID: 28633038 06/21/2017       15 Citations
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017       2 Citations
  • Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. (Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M) J Hematol Oncol 2017 06 12;10(1):117 PMID: 28606176 PMCID: PMC5469142 SCOPUS ID: 2-s2.0-85020468882 06/14/2017       12 Citations
  • PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 07 13;130(2):221-228 PMID: 28468799 PMCID: PMC5510790 SCOPUS ID: 2-s2.0-85023768076 05/05/2017       126 Citations
  • Incidence and survival trends in mantle cell lymphoma. (Epperla N, Hamadani M, Fenske TS, Costa LJ) Br J Haematol 2018 06;181(5):703-706 PMID: 28444739 04/27/2017       19 Citations
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017       4 Citations
  • Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. (Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P) Clin Lymphoma Myeloma Leuk 2017 04;17(4):201-206 PMID: 28395812 SCOPUS ID: 2-s2.0-85017190298 04/12/2017       2 Citations
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. (Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME) J Clin Oncol 2017 Apr 10;35(11):1154-1161 PMID: 28380315 PMCID: PMC5455603 SCOPUS ID: 2-s2.0-85017300040 04/06/2017       227 Citations
  • Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? (Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, Hamadani M) Bone Marrow Transplant 2017 Nov;52(11):1487-1494 PMID: 28368373 04/04/2017       7 Citations
  • Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. (Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P) Biol Blood Marrow Transplant 2017 Jun;23(6):952-957 PMID: 28288949 SCOPUS ID: 2-s2.0-85017516033 03/16/2017       12 Citations
  • Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 05;17(5):305-311.e2 PMID: 28284742 SCOPUS ID: 2-s2.0-85015693044 03/13/2017       4 Citations
  • Treatment of severe mucositis pain with oral ketamine mouthwash. (Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A) Support Care Cancer 2017 07;25(7):2215-2219 PMID: 28190158 PMCID: PMC5500907 02/13/2017       11 Citations
  • Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? (Jethava Y, Guru Murthy GS, Hamadani M) Hematol Oncol Stem Cell Ther 2017 Jun;10(2):47-56 PMID: 28183681 SCOPUS ID: 2-s2.0-85012253423 02/12/2017       6 Citations
  • Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. (Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H) Biol Blood Marrow Transplant 2017 May;23(5):853-856 PMID: 28161608 PMCID: PMC5410937 SCOPUS ID: 2-s2.0-85013473580 02/06/2017       14 Citations
  • Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. (Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P) Clin Lymphoma Myeloma Leuk 2017 03;17(3):165-172 PMID: 28159578 SCOPUS ID: 2-s2.0-85011032026 02/06/2017       10 Citations
  • Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. (Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W) Biol Blood Marrow Transplant 2017 May;23(5):767-775 PMID: 28115276 PMCID: PMC5590102 SCOPUS ID: 2-s2.0-85014101308 01/25/2017       22 Citations
  • Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Dec;35(4):528-535 PMID: 28066928 SCOPUS ID: 2-s2.0-85009230369 01/10/2017       24 Citations
  • Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). (Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston A) Bone Marrow Transplant 2017 02;52(2):321-322 PMID: 27892948 11/29/2016       2 Citations
  • Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. (Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M) Am J Hematol 2017 Feb;92(2):161-170 PMID: 27880984 PMCID: PMC5549936 SCOPUS ID: 2-s2.0-85009832242 11/24/2016       25 Citations
  • Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. (Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Feb;23(2):269-277 PMID: 27864161 PMCID: PMC5346183 SCOPUS ID: 2-s2.0-85008193410 11/20/2016       14 Citations
  • Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. (Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 01;23(1):60-66 PMID: 27789362 PMCID: PMC5182098 SCOPUS ID: 2-s2.0-85006371447 10/30/2016       11 Citations
  • Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN) Biol Blood Marrow Transplant 2016 12;22(12):2117-2125 PMID: 27660167 PMCID: PMC5116249 10/18/2016       42 Citations
  • Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. (Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E) Best Pract Res Clin Haematol 2016 03;29(1):54-66 PMID: 27742072 10/16/2016       4 Citations
  • Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. (Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2016 12;16(12):672-678 PMID: 27660080 SCOPUS ID: 2-s2.0-84997605125 09/24/2016       4 Citations
  • Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. (Epperla N, Olteanu H, Hamadani M) Br J Haematol 2016 12;175(5):758 PMID: 27650173 09/22/2016       2 Citations
  • Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. (Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M) Bone Marrow Transplant 2016 12;51(12):1602-1604 PMID: 27595288 SCOPUS ID: 2-s2.0-84991038636 09/07/2016       6 Citations
  • Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. (DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, Shaw BE) Bone Marrow Transplant 2017 Feb;52(2):173-182 PMID: 27548466 PMCID: PMC5288134 SCOPUS ID: 2-s2.0-84983515188 08/23/2016       16 Citations
  • Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. (Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M) Bone Marrow Transplant 2017 01;52(1):147-150 PMID: 27479688 SCOPUS ID: 2-s2.0-84980370503 08/02/2016       2 Citations
  • Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. (Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A) Future Oncol 2016 Nov;12(22):2631-2642 PMID: 27381652 07/07/2016       7 Citations
  • Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. (Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M) Biol Blood Marrow Transplant 2016 10;22(10):1773-1780 PMID: 27345140 SCOPUS ID: 2-s2.0-84992043960 06/28/2016       3 Citations
  • Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. (Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W) Cancer 2016 10;122(19):3005-3014 PMID: 27315441 PMCID: PMC5030151 SCOPUS ID: 2-s2.0-84978397912 06/18/2016       24 Citations
  • Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. (Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M) J Clin Oncol 2016 09 10;34(26):3141-9 PMID: 27269951 PMCID: PMC5012706 SCOPUS ID: 2-s2.0-84989838395 06/09/2016       133 Citations
  • Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. (DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers MED, Savani BN, Shaw BE, CIBMTR Late Effects and Quality of Life Working Committee, EBMT Complications and Quality of Life Working Party) Biol Blood Marrow Transplant 2016 08;22(8):1493-1503 PMID: 27184625 PMCID: PMC4949101 SCOPUS ID: 2-s2.0-84981340623 05/18/2016       31 Citations
  • Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 07;16(7):379-86 PMID: 27160644 SCOPUS ID: 2-s2.0-84965053091 05/11/2016       8 Citations
  • Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. (Snyder M, Shillingburg A, Newton M, Hamadani M, Kanate AS, Craig M, Cumpston A) Support Care Cancer 2016 10;24(10):4237-40 PMID: 27137211 05/04/2016       3 Citations
  • Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. (Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C) Biol Blood Marrow Transplant 2016 09;22(9):1543-1551 PMID: 27131863 PMCID: PMC4981559 05/02/2016       23 Citations
  • Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. (Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M) Br J Haematol 2016 07;174(2):235-48 PMID: 26989808 PMCID: PMC4940282 SCOPUS ID: 2-s2.0-84978080661 03/19/2016       63 Citations
  • Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. (Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA) Immunotherapy 2016;8(4):435-47 PMID: 26973125 03/15/2016       7 Citations
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. (Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W) Biol Blood Marrow Transplant 2016 06;22(6):1056-1064 PMID: 26964698 PMCID: PMC4877686 SCOPUS ID: 2-s2.0-84963595294 03/12/2016       11 Citations
  • Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. (Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, Hamadani M, Petros W) Antimicrob Agents Chemother 2016 Jan 11;60(3):1830-3 PMID: 26824940 PMCID: PMC4775958 01/30/2016       6 Citations
  • Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. (El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, Kharfan-Dabaja MA) Biol Blood Marrow Transplant 2016 May;22(5):802-14 PMID: 26713431 12/30/2015       15 Citations
  • Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. (Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ, Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium) Am J Hematol 2016 Mar;91(3):322-9 PMID: 26701142 PMCID: PMC4764423 SCOPUS ID: 2-s2.0-84959153683 12/25/2015       37 Citations
  • Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. (Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M) Blood 2016 Feb 18;127(7):938-47 PMID: 26670632 PMCID: PMC4760094 SCOPUS ID: 2-s2.0-84959378642 12/17/2015       156 Citations
  • Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. (Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS) Cytotherapy 2015 Dec;17(12):1785-92 PMID: 26475754 PMCID: PMC4700501 10/18/2015       17 Citations
  • Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. (Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B) Bone Marrow Transplant 2016 Feb;51(2):300-2 PMID: 26457913 SCOPUS ID: 2-s2.0-84956921726 10/13/2015       18 Citations
  • Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. (Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M) Bone Marrow Transplant 2016 Jan;51(1):58-66 PMID: 26437062 PMCID: PMC4703480 SCOPUS ID: 2-s2.0-84953367337 10/06/2015       25 Citations
  • Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. (Epperla N, Fenske TS, Hari PN, Hamadani M) World J Transplant 2015 Sep 24;5(3):81-8 PMID: 26421260 PMCID: PMC4580930 10/01/2015    
  • Ibrutinib in Refractory Classic Hodgkin's Lymphoma. (Hamadani M, Balasubramanian S, Hari PN) N Engl J Med 2015 Oct;373(14):1381-2 PMID: 26422743 SCOPUS ID: 2-s2.0-84942932373 10/01/2015       21 Citations
  • Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. (Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M) J Oncol Pharm Pract 2016 Oct;22(5):666-78 PMID: 26320127 09/01/2015       2 Citations
  • Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. (Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A) Bone Marrow Transplant 2015 Dec;50(12):1513-8 PMID: 26301967 PMCID: PMC4548821 SCOPUS ID: 2-s2.0-84949085500 08/25/2015       21 Citations
  • Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. (Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A) Am J Hematol 2015 Nov;90(11):E212-3 PMID: 26284951 PMCID: PMC4618044 SCOPUS ID: 2-s2.0-84944536944 08/19/2015       7 Citations
  • Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? (Epperla N, Fenske TS, Lazarus HM, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1393-404 PMID: 26281033 08/19/2015       5 Citations
  • Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099 PMID: 26253007 PMCID: PMC4639453 SCOPUS ID: 2-s2.0-84947494295 08/09/2015       37 Citations
  • A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. (Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1416-23 PMID: 26237164 PMCID: PMC4633349 SCOPUS ID: 2-s2.0-84947021369 08/04/2015       32 Citations
  • Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. (Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M, Center for International Blood and Marrow Transplant Research Lymphoma Working Committee) Biol Blood Marrow Transplant 2015 Sep;21(9):1605-11 PMID: 25983043 PMCID: PMC4558181 SCOPUS ID: 2-s2.0-84938993122 05/20/2015       25 Citations
  • The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. (Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W) Biol Blood Marrow Transplant 2015 Oct;21(10):1746-53 PMID: 25981509 PMCID: PMC4568162 SCOPUS ID: 2-s2.0-84941315276 05/20/2015       25 Citations
  • Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. (Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS) Antimicrob Agents Chemother 2015 Aug;59(8):4424-8 PMID: 25987632 PMCID: PMC4505228 05/20/2015       43 Citations
  • Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. (Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL) Bone Marrow Transplant 2015 Aug;50(8):1057-62 PMID: 25915806 PMCID: PMC4527880 SCOPUS ID: 2-s2.0-84938988030 04/29/2015       12 Citations
  • Secondary solid cancer screening following hematopoietic cell transplantation. (Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS) Bone Marrow Transplant 2015 Aug;50(8):1013-23 PMID: 25822223 PMCID: PMC4989866 SCOPUS ID: 2-s2.0-84938971140 03/31/2015       68 Citations
  • A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. (Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM) Clin Lymphoma Myeloma Leuk 2015 Jul;15(7):428-432.e2 PMID: 25776192 PMCID: PMC4484305 03/18/2015       51 Citations
  • Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. (Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2015 Jul;21(7):1155-66 PMID: 25769794 SCOPUS ID: 2-s2.0-84930577739 03/15/2015       71 Citations
  • Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. (Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M) Bone Marrow Transplant 2015 Apr;50(4):610-2 PMID: 25621807 SCOPUS ID: 2-s2.0-84926418285 01/27/2015       5 Citations
  • Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. (Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2015 Mar;21(3):552-8 PMID: 25528388 PMCID: PMC4329042 SCOPUS ID: 2-s2.0-84922826985 12/22/2014       6 Citations
  • Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG) Lancet Oncol 2014 Dec;15(13):1503-1512 PMID: 25456369 SCOPUS ID: 2-s2.0-84925230724 12/03/2014       191 Citations
  • Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. (Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):199-207 PMID: 25445467 12/03/2014       2 Citations
  • Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. (Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN) Bone Marrow Transplant 2015 Mar;50(3):449-51 PMID: 25387097 SCOPUS ID: 2-s2.0-84930383567 11/12/2014       4 Citations
  • Autologous hematopoietic cell transplantation: an update for clinicians. (Hamadani M) Ann Med 2014 Dec;46(8):619-32 PMID: 25211470 09/12/2014       8 Citations
  • Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 PMID: 25111581 SCOPUS ID: 2-s2.0-84912142377 08/12/2014       19 Citations
  • Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. (Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK) Biol Blood Marrow Transplant 2014 Nov;20(11):1729-36 PMID: 25008330 PMCID: PMC4194275 SCOPUS ID: 2-s2.0-84908019168 07/11/2014       54 Citations
  • Reply to S. Fuji et al. (Hamadani M, Vos JA, Craig MD) J Clin Oncol 2014 Jun 10;32(17):1860-1 PMID: 24799471 05/07/2014    
  • Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 SCOPUS ID: 2-s2.0-84900867182 05/03/2014       6 Citations
  • Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. (Kanate AS, Pasquini MC, Hari PN, Hamadani M) World J Stem Cells 2014 Apr 26;6(2):69-81 PMID: 24772235 PMCID: PMC3999783 04/29/2014    
  • Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. (McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ) Biol Blood Marrow Transplant 2014 Jul;20(7):960-8 PMID: 24641829 PMCID: PMC4057955 SCOPUS ID: 2-s2.0-84902120179 03/20/2014       27 Citations
  • Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. (Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W) Biol Blood Marrow Transplant 2014 Jul;20(7):951-9 PMID: 24641828 PMCID: PMC4060436 SCOPUS ID: 2-s2.0-84902084890 03/20/2014       23 Citations
  • Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. (Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA) Semin Hematol 2014 Jan;51(1):73-86 PMID: 24468319 01/29/2014       8 Citations
  • Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. (Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I) Biol Blood Marrow Transplant 2014 May;20(5):646-54 PMID: 24462982 01/28/2014       21 Citations
  • Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! (Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN) Bone Marrow Transplant 2014 May;49(5):599-606 PMID: 24442246 01/21/2014       20 Citations
  • Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter? (Hamadani M) Biol Blood Marrow Transplant 2014 Mar;20(3):292-4 PMID: 24394802 01/08/2014       2 Citations
  • Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. (Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS) Biol Blood Marrow Transplant 2014 Mar;20(3):415-20 PMID: 24361913 PMCID: PMC4557764 12/24/2013       12 Citations
  • Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. (Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN) J Clin Oncol 2014 Feb 01;32(4):273-81 PMID: 24344210 PMCID: PMC3897255 SCOPUS ID: 2-s2.0-84897020212 12/18/2013       81 Citations
  • Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. (Hamadani M, Gibson LF, Remick SC, Wen S, Petros W, Tse W, Brundage KM, Vos JA, Cumpston A, Bunner P, Craig MD) J Clin Oncol 2013 Dec 10;31(35):4416-23 PMID: 24166529 PMCID: PMC3842909 10/30/2013       19 Citations
  • Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. (Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2014 Jan;20(1):89-97 PMID: 24161923 PMCID: PMC3886623 SCOPUS ID: 2-s2.0-84890911661 10/29/2013       70 Citations
  • Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. (Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M) Clin Lymphoma Myeloma Leuk 2014 Feb;14(1):50-5 PMID: 24119465 10/15/2013       21 Citations
  • Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. (Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston A) Ann Hematol 2014 Apr;93(4):677-82 PMID: 24097085 10/08/2013       12 Citations
  • Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas. (Hamadani M, Kanate AS) Community Oncology Hamadani M., Kanate AS.: “Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas.” Community Oncology. 2013 October;10(10):279-281 10/01/2013    
  • Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. (Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W) Blood 2013 Dec 05;122(24):3863-70 PMID: 24065243 PMCID: PMC3854108 SCOPUS ID: 2-s2.0-84891072099 09/26/2013       99 Citations
  • Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. (Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A) Br J Haematol 2013 Nov;163(3):315-25 PMID: 24033280 09/17/2013       27 Citations
  • Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. (Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M) J Clin Apher 2013 Oct;28(5):359-67 PMID: 23765597 SCOPUS ID: 2-s2.0-84885958621 06/15/2013       20 Citations
  • Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. (Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M) Bone Marrow Res 2013;2013:414959 PMID: 23691325 PMCID: PMC3652129 05/22/2013    
  • Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes. (Kanate AS, Watkins K, Cumpston A, Craig M, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1133-5 PMID: 23635452 05/03/2013       4 Citations
  • Management strategies for follicular lymphoma patients in remission after modern frontline chemoimmunotherapies. (Chaudhary L, Hamadani M) Journal of Blood Disorders & Transfusion Chaudhary L, Hamadani M (2012) Management Strategies for Follicular Lymphoma patients in Remission after Modern Frontline Chemoimmunotherapies. J Blood Disorders Transf 3:e105 05/01/2013    
  • Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. (Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M) Biol Blood Marrow Transplant 2013 Sep;19(9):1288-300 PMID: 23618718 04/27/2013       7 Citations
  • Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? (Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M) Bone Marrow Transplant 2013 Nov;48(12):1489-96 PMID: 23584438 SCOPUS ID: 2-s2.0-84889590282 04/16/2013       8 Citations
  • Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. (Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M) Bone Marrow Transplant 2013 Oct;48(10):1279-84 PMID: 23584435 04/16/2013       32 Citations
  • Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. (Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1006-12 PMID: 23396213 02/12/2013       55 Citations
  • Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM) Biol Blood Marrow Transplant 2013 May;19(5):746-53 PMID: 23380340 PMCID: PMC3650915 SCOPUS ID: 2-s2.0-84876298990 02/06/2013       49 Citations
  • Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM) Biol Blood Marrow Transplant 2013 Apr;19(4):625-31 PMID: 23333532 PMCID: PMC3640440 SCOPUS ID: 2-s2.0-84875481784 01/22/2013       41 Citations
  • Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. (Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A) J Hematol Oncol 2013 Jan 04;6:2 PMID: 23289975 PMCID: PMC3548722 01/08/2013       31 Citations
  • Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit. (Cumpston A, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR) Transpl Infect Dis 2013 Apr;15(2):142-9 PMID: 23279656 01/03/2013       18 Citations
  • Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. (Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL) Biol Blood Marrow Transplant 2013 Feb;19(2):173-9 PMID: 23200705 PMCID: PMC3553321 SCOPUS ID: 2-s2.0-84872527502 12/04/2012       22 Citations
  • Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. (Kanate AS, Kharfan-Dabaja MA, Hamadani M) Bone Marrow Res 2012;2012:897215 PMID: 23097707 PMCID: PMC3477524 10/26/2012    
  • Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. (Ross AL, Slain D, Cumpston A, Bryant AM, Hamadani M, Craig M) Int J Antimicrob Agents 2012 Dec;40(6):557-61 PMID: 23068599 10/17/2012       12 Citations
  • Rituximab maintenance versus retreatment in follicular lymphoma. (Palla AR, Hamadani M) Hematol Oncol 2013 Dec;31(4):171-8 PMID: 23044794 10/10/2012       3 Citations
  • Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? (Hamadani M) Bone Marrow Transplant 2013 Aug;48(8):1013-21 PMID: 23000653 09/25/2012       12 Citations
  • Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit. (Sweet MA, Cumpston A, Briggs F, Craig M, Hamadani M) Am J Infect Control 2012 Dec;40(10):931-4 PMID: 22575286 05/12/2012       48 Citations
  • Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. (Awan FT, Kochuparambil ST, Deremer D, Cumpston A, Craig M, Jillella A, Hamadani M) J Oncol 2012;2012:931071 PMID: 22570654 PMCID: PMC3335320 05/10/2012    
  • Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. (Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W) Biol Blood Marrow Transplant 2012 Sep;18(9):1446-54 PMID: 22449610 PMCID: PMC3499973 SCOPUS ID: 2-s2.0-84865198731 03/28/2012       15 Citations
  • Regulation of acute graft-versus-host disease by microRNA-155. (Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R) Blood 2012 May 17;119(20):4786-97 PMID: 22408260 PMCID: PMC3367879 03/13/2012       97 Citations
  • Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. (Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F) Biol Blood Marrow Transplant 2012 Jul;18(7):1128-35 PMID: 22248715 01/18/2012       47 Citations
  • Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. (Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, Hamadani M) Hematol Oncol Stem Cell Ther 2011;4(4):149-56 PMID: 22198185 12/27/2011    
  • Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Mohty M, Kharfan-Dabaja MA) Cancer Control 2011 Oct;18(4):237-45 PMID: 21976242 10/07/2011    
  • CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells. (Liu K, Anthony BA, Yearsly MM, Hamadani M, Gaughan A, Wang JJ, Devine SM, Hadley GA) PLoS One 2011;6(7):e21968 PMID: 21779359 PMCID: PMC3136479 07/23/2011       8 Citations
  • Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. (Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN) Blood 2011 Aug 18;118(7):1979-88 PMID: 21690560 PMCID: PMC3158724 SCOPUS ID: 2-s2.0-80051878404 06/22/2011       59 Citations
  • Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. (Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM) Hematol Oncol 2011 Dec;29(4):202-10 PMID: 21360728 PMCID: PMC3557914 03/02/2011       12 Citations
  • Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. (Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M) Bone Marrow Transplant 2012 Jan;47(1):146-8 PMID: 21358681 03/02/2011       4 Citations
  • The evolving role of statins in hematopoietic stem and progenitor cell transplantation. (Hamadani M, Craig MD, Gibson LF, Remick SC) Am J Blood Res 2011;1(1):57-64 PMID: 22432066 PMCID: PMC3301410 01/01/2011    
  • Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. (Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA) J Clin Oncol 2010 Nov 01;28(31):e629-32 PMID: 20733121 08/25/2010       26 Citations
  • How we approach patient evaluation for hematopoietic stem cell transplantation. (Hamadani M, Craig M, Awan FT, Devine SM) Bone Marrow Transplant 2010 Aug;45(8):1259-68 PMID: 20479713 05/19/2010       46 Citations
  • Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis. (Hamadani M, Awan F, Villalona-Calero MA) Am J Clin Oncol 2010 Feb;33(1):109 PMID: 20139744 02/09/2010       3 Citations
  • Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. (Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM) Leuk Lymphoma 2010 Feb;51(2):243-51 PMID: 20038230 PMCID: PMC3557809 12/30/2009       14 Citations
  • Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. (Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM) Biol Blood Marrow Transplant 2009 Nov;15(11):1422-30 PMID: 19822302 PMCID: PMC3953136 10/14/2009       62 Citations
  • Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. (Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA) Br J Haematol 2010 Feb;148(4):623-6 PMID: 19821825 10/14/2009       2 Citations
  • Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. (Hamadani M, Devine SM) Blood 2009 Sep 17;114(12):2564-6 PMID: 19762505 09/19/2009       9 Citations
  • Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. (Hamadani M, Awan FT) Hematol Oncol 2010 Mar;28(1):3-12 PMID: 19645073 08/01/2009       5 Citations
  • Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. (Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM) Biol Blood Marrow Transplant 2009 May;15(5):547-53 PMID: 19361746 PMCID: PMC3953134 04/14/2009       35 Citations
  • Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. (Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC) Leuk Lymphoma 2009 Mar;50(3):349-56 PMID: 19263294 PMCID: PMC3695225 03/06/2009       5 Citations
  • Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Blum W) Clinical Leukemia Hamadani M., Blum W.: “Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia.” Clinical Leukemia. 2009 February;3(1):47-57 02/01/2009    
  • Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM) Leuk Lymphoma 2008 Oct;49(10):1893-8 PMID: 18949613 10/25/2008       8 Citations
  • Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? (Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzoni M) J Clin Oncol 2008 Nov 01;26(31):5134-6; author reply 5136-7 PMID: 18838697 10/08/2008       52 Citations
  • High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM) Eur J Haematol 2008 Dec;81(6):425-31 PMID: 18774954 09/09/2008       25 Citations
  • Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. (Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM) Biol Blood Marrow Transplant 2008 Jul;14(7):783-9 PMID: 18541197 PMCID: PMC4100722 06/11/2008       43 Citations
  • Review: isolated skeletal involvement in hairy cell leukemia. (Hamadani M, Kraut EH) Clin Adv Hematol Oncol 2008 Apr;6(4):294-6 PMID: 18496496 05/23/2008       1 Citation
  • Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Awan FT, Copelan EA) Biol Blood Marrow Transplant 2008 May;14(5):556-67 PMID: 18410898 04/16/2008       37 Citations
  • The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. (Hamadani M, Awan FT, Devine SM) Blood 2008 Apr 01;111(7):3901-2 PMID: 18362217 03/26/2008       37 Citations
  • Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM) Biol Blood Marrow Transplant 2008 Apr;14(4):480-3 PMID: 18342792 03/18/2008       27 Citations
  • The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. (Hamadani M, Hade E, Benson DM Jr, Hofmeister CC) Biol Blood Marrow Transplant 2008 Mar;14(3):351-2 PMID: 18275902 02/16/2008       7 Citations
  • False-negative PET scan with bronchioloalveolar carcinoma: an important diagnostic caveat. (Awab A, Hamadani M, Peyton M, Brown B) Am J Med Sci 2007 Oct;334(4):311-3 PMID: 18030191 11/22/2007       8 Citations
  • An unusual etiology of chest pain. (Rashid A, Afaq A, Hamadani M, Warraich J, Hennebry T) J Okla State Med Assoc 2007 Sep;100(9):352-3 PMID: 18020040 11/21/2007    
  • CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). (Hamadani M, Magro CM, Porcu P) Br J Haematol 2008 Jan;140(2):122 PMID: 17991297 11/10/2007       2 Citations
  • Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? (Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A) J Oncol Pharm Pract 2007 Jun;13(2):69-75 PMID: 17873106 SCOPUS ID: 2-s2.0-34548623153 09/18/2007       21 Citations
  • Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. (Vrindavanam N, Hamadani M, Steele B, Awan F, Suster S, Benson DM Jr) Am J Hematol 2007 Dec;82(12):1120-1 PMID: 17654679 SCOPUS ID: 2-s2.0-36749033711 07/27/2007       2 Citations
  • Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. (Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM) Transpl Infect Dis 2008 Feb;10(1):24-6 PMID: 17651365 07/27/2007       11 Citations
  • Gastrointestinal chronic graft-versus-host disease: management options. (Awan F, Hamadani M) J Oncol Pharm Pract 2007 Mar;13(1):49-51 PMID: 17621568 07/11/2007       1 Citation
  • Thalidomide-induced fulminant hepatic failure. (Hamadani M, Benson DM Jr, Copelan EA) Mayo Clin Proc 2007 May;82(5):638 PMID: 17493431 05/12/2007    
  • Paraneoplastic Sweet's syndrome and the pathergy phenomenon. (Awan F, Hamadani M, Devine S) Ann Hematol 2007 Aug;86(8):613-4 PMID: 17468870 05/01/2007       13 Citations
  • Gastroparesis. (Ali T, Hasan M, Hamadani M, Harty RF) South Med J 2007 Mar;100(3):281-6 PMID: 17396732 04/03/2007       23 Citations
  • Limitations of Sokal score in patients with chronic myeloid leukemia. (Hamadani SM, Chaudhary L) J Coll Physicians Surg Pak 2007 Mar;17(3):182; author reply 182 PMID: 17374310 03/22/2007    
  • Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. (Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC) Bone Marrow Transplant 2007 Feb;39(4):249-51 PMID: 17290281 02/10/2007       14 Citations
  • McCune-Albright syndrome. (Hamadani M, Chaudhary L) Med J Aust 2006 Dec 4-18;185(11-12):597 PMID: 17181499 SCOPUS ID: 2-s2.0-33846109352 12/22/2006       1 Citation
  • Role of thiamine in managing ifosfamide-induced encephalopathy. (Hamadani M, Awan F) J Oncol Pharm Pract 2006 Dec;12(4):237-9 PMID: 17156595 12/13/2006       32 Citations
  • Early detection of digitalis-induced nonocclusive mesenteric ischemia using Doppler ultrasonography. (Awab A, Hamadani M, Saya S, Whitsett T) South Med J 2006 Oct;99(10):1142 PMID: 17100040 11/15/2006       1 Citation
  • Infected atrial myxoma. (Awab A, Hamadani M, Sud B, Voskuhl GW) Med J Aust 2006 Sep 18;185(6):332 PMID: 16999677 09/27/2006       4 Citations
  • Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy. (Hamadani M, Awab A, Chaudhary L, Tfayli A) J Oncol Pharm Pract 2006 Jun;12(2):67-8 PMID: 16984743 SCOPUS ID: 2-s2.0-34248191058 09/21/2006       3 Citations
  • Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. (Tfayli A, Selby G, Maqbool F, Bierbaum W, Hamadani M) Am J Hematol 2006 Dec;81(12):959-62 PMID: 16924649 08/23/2006       11 Citations
  • Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome. (Hamadani M, Awab A, Rashid A, Ali T, Brown B) J Coll Physicians Surg Pak 2006 May;16(5):376-7 PMID: 16756788 06/08/2006       3 Citations
  • Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. (Hamadani M, Kharfan-Dabaja M, Kamble R, Kern W, Ozer H) J Okla State Med Assoc 2006 Apr;99(4):154-6 PMID: 16703935 05/18/2006       9 Citations
  • Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. (Kamble RT, Hamadani M, Selby GB) J Antimicrob Chemother 2006 Apr;57(4):795-6 PMID: 16476723 02/16/2006       1 Citation
  • Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance. (Kamble RT, Hamadani M, Selby GB) Biol Blood Marrow Transplant 2006 Jan;12(1):111-2 PMID: 16399575 01/10/2006       1 Citation
  • Granulocytic sarcoma manifesting as multiple skeletal lesions. (Hamadani M, Tfayli A, Sethi S, Awab A, Hamdani N) Am J Med Sci 2005 Sep;330(3):139-43 PMID: 16174998 09/22/2005       11 Citations
  • Last update: 11/23/2020
    jenkins-FCD Prod-484 8aa07fc50b7f6d102f3dda2f4c7056ff84294d1d